Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Emily Pollard

Pain Medicine Oklahoma City, OK Medical Doctor

NPI 1629456504 CMS profile 5567268

1810 E Memorial Rd, Oklahoma City, OK 73131

Open in the dashboard

General payments

$134,270

510 records reported · program years 2019–2025

Research payments

$1,025

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Emily Pollard of Oklahoma City, OK is reported in the CMS Open Payments database as having received $134,270 across 510 general payments and $1,025 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $27,749 93
2024 General $43,904 152
2023 General $50,456 116
2022 General $5,978 66
2021 General $3,796 51
2021 Research $1,025 1
2020 General $985 18
2019 General $1,401 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Emily Pollard
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Emily Pollard were reported at $27,749. Among 757 Pain Medicine profiles paid that year, the median was $470 and the middle half received between $146 and $1,462.

Show as a table
Year Emily Pollard Pain Medicine median Middle half National median
2019 $1,401 $506 $144–$1,566 $163
2020 $985 $315 $96–$934 $114
2021 $3,796 $452 $134–$1,237 $132
2022 $5,978 $475 $124–$1,407 $149
2023 $50,456 $480 $136–$1,384 $160
2024 $43,904 $521 $164–$1,511 $164
2025 $27,749 $470 $146–$1,462 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $113,485 325 payments
  2. Medtronic, Inc. $12,918 87 payments
  3. Vertos Medical, Inc. $1,949 9 payments
  4. Abbott Laboratories $1,662 11 payments
  5. Nevro Corp. $1,322 26 payments
  6. Relievant Medsystems, Inc. $983 11 payments
  7. Medtronic USA, Inc. $660 10 payments
  8. SI-BONE, Inc. $407 6 payments
  9. Nalu Medical, Inc. $332 6 payments
  10. Spinal Simplicity, LLC $181 2 payments
  11. Other $372 17 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $94,194 63 payments
  2. Travel and Lodging $19,584 87 payments
  3. Food and Beverage $15,891 351 payments
  4. Consulting Fee $4,325 7 payments
  5. Education $277 2 payments
Products named General payments · program years 2019–2025
  1. WaveWriter Alpha Prime 16 $18,689 100 payments
  2. General - Therapies $10,472 19 payments
  3. INTELLIS ADAPTIVESTIM $6,815 30 payments
  4. Superion Indirect Decompression System $6,748 8 payments
  5. VANTA ADAPTIVESTIM $2,171 10 payments
  6. mild Device Kit $1,949 9 payments
  7. INTELLIS $1,423 18 payments
  8. SYNCHROMEDII $1,344 16 payments
  9. Intracept Pain $983 11 payments
  10. Intracept Pain $983 11 payments
  11. Other $9,323 161 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medtronic, Inc. $1,025 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

2,494

Median for Pain Management: 951

Drug cost

$40,886

Median for Pain Management: $26,034

Branded share of claims

19.3%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Pregabalin Generic 743 $8,939
Buprenorphine Generic 45 $6,629
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 336 $5,001
Gabapentin Generic 411 $4,184
Duloxetine Hcl Generic 144 $3,452
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 82 $2,521
Xtampza Er Oxycodone Myristate Brand 13 $2,502
Lidocaine Generic 13 $1,326
Oxycodone Hcl Generic 58 $1,161
Naloxone Hcl Generic 15 $953

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 81 billing codes

Paid by Medicare

$863,649

Of which drugs: $4,032

Medicare patients

845

Average age 75

Services billed

11,872

511 women, 334 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 36%
Diabetes 30%
Chronic kidney disease 23%
Depression 21%
Atrial fibrillation 19%
Osteoporosis 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 513 7,806 $667

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

511 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record